Table 1 Basic characteristics of included RCTs
From: Comparative efficacy of treatments for patients with knee osteoarthritis: a network meta-analysis
| Author, year, country | Disease degree | Treatments | Size | Age | Male (%) | BMI | Dosage | No. of injection | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Yu, 2018, China | KL grade I–IV | PRP | 104 | 46.2 | 48.10 | 8 ml PRP | 5 | 52 weeks | |
| HA | 88 | 51.5 | 54.50 | 0.2 mg HA | 5 | 52 weeks | |||
| PRP + HA | 96 | 46.5 | 52.10 | 8 ml PRP + 0.2 mg HA | 5 | 52 weeks | |||
| Placebo | 72 | 56.2 | 58.30 | NM | 5 | 52 weeks | |||
| Rahimzadeh, 2018, Iran | KL grade I–II | PRP | 21 | 65.5 | 47.60 | 7 ml PRP | 1 | 26 weeks | |
| Placebo | 21 | 64.3 | 52.40 | 28.6 | 7 ml 25% dextrose | 1 | 26 weeks | ||
| McAlindon, 2017, American | ACR criteria; KL grade II–III | Corticosteroid | 70 | 59.1 | 47.10 | 28.3 | 4 mg corticosteroid | 8 | 2 years |
| Placebo | 70 | 57.2 | 45.70 | 30.8 | 1 ml saline | 8 | 2 years | ||
| Tammachote, 2016, Thailand | ACR criteria | HA | 50 | 62.6 | 14.00 | 31.7 | 6 ml HA | 1 | 26 weeks |
| Corticosteroid | 49 | 61 | 26.00 | 40 mg TA | 1 | 26 weeks | |||
| Cole, 2016, American | KL grade I–III | PRP | 49 | 55.9 | 56.00 | 4 ml PRP | 3 | 52 weeks | |
| HA | 50 | 56.8 | 60.00 | 27.4 | 16 mg | 3 | 52 weeks | ||
| Paterson, 2016, Australia | ACR criteria; KL grade II–III | PRP | 11 | 49.9 | 72.73 | 29 | 3 ml PRP | 1 | 12 weeks |
| HA | 10 | 52.7 | 70.00 | 27.9 | 3 ml HA | 1 | 12 weeks | ||
| Lana, 2016, American | KL grade I–III | HA | 36 | 60 | 91.70 | 30.9 | 20 mg HA | 3 | 52 weeks |
| PRP | 36 | 60.9 | 80.60 | 28.2 | 5 ml PRP | 3 | 52 weeks | ||
| PRP + HA | 33 | 62 | 81.80 | 27.4 | 20 mg HA + 5 ml PRP | 3 | 52 weeks | ||
| Askari, 2016, Iran | KL grade II–III | Corticosteroid | 69 | 17.40 | 29.2 | 2 cc HA | 1 | 13 weeks | |
| HA | 71 | 12.70 | 40 mg corticosteroid | 1 | 13 weeks | ||||
| Forogh, 2016, Iran | KL grade II-III | PRP | 24 | 59.1 | 29.20 | 5 ml PRP | 1 | 26 weeks | |
| Corticosteroid | 24 | 61.1 | 37.50 | 75.8 | 40 mg corticosteroid | 1 | 26 weeks | ||
| Filardo, 2015, American | KL grade I–III | PRP | 94 | 53.3 | 63.80 | 75.8 | 5 ml PRP | 3 | 52 weeks |
| HA | 89 | 57.6 | 58.40 | 26.6 | 2 ml HA | 3 | 52 weeks | ||
| Rayegani, 2014, Iran | ACR criteria; KL grade I–IV | PRP | 31 | 58.1 | 6.50 | 26.9 | 4–6 ml PRP | 2 | 26 weeks |
| Placebo | 31 | 54.7 | 6.50 | 28.2 | NM | NM | 26 weeks | ||
| Patel, 2013, India | ACR criteria; Ahlbäck grade I–II | PRP | 27 | 53.1 | 40.70 | 27.3 | 8 ml PRP | 1 | 26 weeks |
| Placebo | 23 | 53.7 | 26.00 | 26.3 | 8 ml saline | 1 | 26 weeks | ||
| Filardo, 2012, Italy | KL grade I–III | PRP | 54 | 55 | 68.50 | 26.2 | 5 ml PRP | 3 | 52 weeks |
| HA | 55 | 58 | 56.40 | 27 | NM | 3 | 52 weeks | ||
| Huang, 2011, China | ACR criteria; KL grade II––III | HA | 100 | 65.9 | 26.00 | 26 | 20 mg HA | 5 | 25 weeks |
| Placebo | 100 | 64.2 | 22.00 | 25.7 | 2 ml saline | 5 | 25 weeks | ||
| Diracoglu, 2009, Turkey | ACR criteria; KL grade II–III | HA | 40 | 25.4 | NM | 1 | 26 weeks | ||
| Placebo | 20 | NM | 1 | 26 weeks | |||||
| Lundsgaard, 2008, Denmark | KL grade I–IV | HA | 84 | 68.8 | 42.9 | 2 ml HA | 4 | 52 weeks | |
| Placebo | 84 | 69.6 | 47.60 | 29.6 | 2 ml saline | 4 | 52 weeks | ||
| Ubuku, 2004, Turkey | ACR criteria | HA | 20 | 52.6 | 30.00 | 29.3 | 2 ml HA | 1 | 8 weeks |
| Placebo | 10 | 57.6 | 0.00 | 2 ml saline | 1 | 8 weeks | |||
| Altman, 2004, American | ACR criteria | HA | 172 | 62.9 | 54.00 | 60 mg HA | 1 | 26 weeks | |
| Placebo | 174 | 63.3 | 36.00 | 3 ml 0.9% saline | 1 | 26 weeks | |||
| Karlsson, 2002, Sweden | Ahlbäck grade I–II | HA | 76 | 35.00 | 4.5 ml HA | 3 | 52 weeks | ||
| Placebo | 57 | 39.00 | 3 ml saline | 3 | 52 weeks |